Call for Abstract

  • University of Montreal, Canada

    University of Washington, USA

    Tanzania Vaccine Institute, Tanzania

    Alexandria University, Egypt

    Lanzhou Veterinary Research Institute, China

    Sassari University School of Medicine, Italy

    The University of Melbourne, Australia

    Technical University of Braunschweig, Germany

    Tsukuba Primate Research Center, Japan

    Vaccines and Sera Torlak, Serbia

    Emory University, USA

    Faculdade de Medicina Santo, Brazil

    Centro de Ingenieria Genetica y Biotecnologia, Cuba

    University of KwaZulu-Natal, Belgium

    National Health Research Institute, Taiwan

    Korea University, Korea

    Center for Genetic Engineering and Biotechnology, Cuba

    Indonesian Technical Advisory Committee on Immunization, Indonesia

    Walter Reed Army Institute of Research, USA


    Karolinska Institutet, Sweden

    Gulu University, Uganda

    The Royal Children’s Hospital, Australia

    University of Groningen, Netherlands

    Central Institute for Research on Goats, India

    INSERM, France

    University of Sarajevo, Bosnia and Herzegovina

    University of British Columbia, Canada

    Temple University Center for Biotechnology, USA

    UC Davis School of Medicine, USA

    The Scripps Research Institute, USA

    The University of Tokyo, Japan

    Texas Biomedical Research Institute, USA

    Flinders University, Australia

    The George Washington University, USA

    The University of Adelaide, South Australia

    University of Michigan Medical School, USA

    University of Louisville, USA

    National Centre for Biotechnology, Spain

    Pontifical Universtity of Salamanca, Spain

    Universidade Federal de Goias, Brazil

    JJ Strossmayer University, Croatia

    Tehran University of Medical Sciences, Iran

    Medical University of Vienna, Austria

    University of Bedfordshire, UK

    University of Oxford, UK

    The Tazuke Kofukai Medical Research Institute, Japan

    Pasteur Institute of Iran, Iran

    Palacky University, Czech Republic

    The University of Western Ontario, Canada

    Chonbuk National University, South Korea

  • Liquidia Technologies Inc., USA

    Profectus BioSciences, Inc., USA

    Prokarium Ltd., UK

    FluGen Inc., USA

    Novartis Vaccines, USA

    Merck & Co., Inc., USA

    Arbovax Inc., USA

    Merck Millipore, Europe

    Sanofi Pasteur, USA

    UNIVAC llc, Belgium

    Bavarian Nordic, Germany

    VALNEVA, Austria

    Cellular Technology Limited, USA

    Celldex Therapeutics, USA

    Serum Institute of India, India

    Vedantra Pharmaceuticals, USA

    Shanghai Zerun Biotechnology Co .,Ltd. China

    GenPhar Inc., USA

    InnaVirVax, USA

    West Pharmaceutical Services, USA

    Inovio Pharmaceuticals, USA

    VaxInnate Corporation, USA

    Vaxart, Inc., USA

    Iliad Biotechnologies, Scotland

    European Institute of Innovation and Technology, Europe

    REIMS, France

    International Vaccine Institute, Korea

    Micronutrient Initiative, Bangladesh

    Slovak Academy of Sciences, Solvakia


5th Asia Pacific Global Summit and Expo on Vaccines & Vaccination, will be organized around the theme “Vaccine Research: From Bench to Bedside”

Vaccines Asia Pacific-2015 is comprised of 22 tracks and 121 sessions designed to offer comprehensive sessions that address current issues in Vaccines Asia Pacific-2015.

Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Recent trends in vaccines development path
  • Track 1-2Current technologies using in vaccines discovery
  • Track 1-3New vaccines against infectious diseases
  • Track 1-4Recent technologies in modifying bacterial genome
  • Track 2-1New approaches to combat bacterial pathogens
  • Track 2-2Public health concerns in vaccination
  • Track 2-3Contraindications of vaccinations
  • Track 2-4Vaccines formulation and technologies used in conjugated vaccines
  • Track 2-5Vaccine resistance and need of Next-Gen Conjugate Vaccines
  • Track 2-6Others
  • Track 3-1Challenges and Innovation
  • Track 3-2Planning
  • Track 3-3Business Development of Animal Vaccines
  • Track 3-4Business Development of Human Vaccines
  • Track 3-5Phyto vaccines
  • Track 4-1Major discoveries in carbohydrate based vaccines
  • Track 4-2Glycomics- Vaccine Discoveries
  • Track 4-3Identification, synthesis and evaluation of unique glycan epitopes
  • Track 4-4Targeting the surface carbohydrates of infectious agents
  • Track 4-5Role of carbohydrate-based vaccines in cancer therapy
  • Track 4-6Others
  • Track 5-1Whooping cough Vaccines in pregnant women
  • Track 5-2Immunization before pregnancy
  • Track 5-3Immunization during pregnancy
  • Track 5-4Consequences of halting vaccination in pregnancy
  • Track 5-5Chiropractic vaccination care in women and pregnancy
  • Track 5-6Others
  • Track 6-1Bovine vaccine technology
  • Track 6-2Pet vaccines and vaccination
  • Track 6-3Animal health outcomes
  • Track 6-4Animal diseases and vaccination
  • Track 6-5Current status of veterinary vaccines
  • Track 6-6Others
  • Track 7-1Designing of adjutvants
  • Track 7-2Rationale selection of adjuvants
  • Track 7-3Skin delivery techniques
  • Track 7-4Adjuvant interactions
  • Track 7-5BeneficialAdjuvents
  • Track 7-6Others
  • Track 8-1Peptide Based vaccines
  • Track 8-2Protein based vaccines
  • Track 8-3Others
  • Track 9-1Conjugated vaccine discovery and translation of new vaccine technology
  • Track 9-2Safety, immunogenicity, and induction of immunologic memory by a serogroup C meningococcal conjugate vaccine in infants
  • Track 9-3Production of Conjugate Vaccines Using Recombinant DNA Technology
  • Track 9-4Manufacturing of Conjugate Vaccines
  • Track 9-5Effect of pneumococcal conjugate vaccine on pneumococcal meningitis
  • Track 9-6Others
  • Track 10-1Yellow fever: Epidemiology and prevention
  • Track 10-2Typhoid fever vaccination
  • Track 10-3Advantage of live attenuated vaccines
  • Track 10-4Risk factors in unsing live attenuated vaccines
  • Track 10-5Tubercular vaccination
  • Track 10-6Cancer Therapeutic Vaccination
  • Track 10-7Others
  • Track 11-1Preclinical stage development and factors affecting
  • Track 11-2Clinical stage process
  • Track 11-3Vaccines efficacy testing
  • Track 11-4Manufacture of the vaccine to Good Manufacturing Practice standards
  • Track 11-5Complications and consequences affecting vaccine development
  • Track 11-6Others
  • Track 12-1Safety considerations in vaccination
  • Track 12-2Vaccines and vaccination knowledge
  • Track 12-3Health care outcomes of different aged people vaccinated
  • Track 12-4Safety and efficacy of vaccines
  • Track 12-5Vaccines and vaccination- health care improvement.
  • Track 12-6Others
  • Track 13-1Role of nanotechnology in vaccine delivery
  • Track 13-2Hepatitis B virus spread and control
  • Track 13-3Recombinant technology usage
  • Track 13-4Virus-like particles as vaccines, vectors and adjutants
  • Track 13-5Vaccines and its target compositions
  • Track 13-6Others
  • Track 14-1Tetanus, diphtheria, acellular pertussis vaccine during pregnancy
  • Track 14-2Diphtheria and tetanus toxoids usage in pediatrics
  • Track 14-3Administration and routes of administration of toxoids
  • Track 14-4Innovative toxoid vaccine development
  • Track 14-5Maternal immunization
  • Track 14-6Others
  • Track 15-1Immunization and its side effects in geriatrics
  • Track 15-2Vaccine dosing and administration in older adults
  • Track 15-3Herpes zoster vaccine
  • Track 15-4Pneumococcal polysaccharide vaccine
  • Track 15-5Contraindications and precautions during vaccination in geriatrics
  • Track 15-6Risk factors in geriatric immunization
  • Track 15-7Others
  • Track 16-1HIV vaccine
  • Track 16-2Ebola vaccine
  • Track 16-3Cancer vaccination
  • Track 16-4Vaccine for severe acute respiratory syndrome
  • Track 16-5Need of vaccination for major diseases
  • Track 16-6Others
  • Track 17-1Dendritic cell based vaccines and development
  • Track 17-2Recombinent vector based immunization
  • Track 17-3DNA Vaccination
  • Track 17-4T-cell receptor peptide vaccines
  • Track 17-5Targeted bacterial protein identification
  • Track 17-6Others
  • Track 19-1Mucosal Vaccines Design
  • Track 19-2Mucosal Vaccines Delivery
  • Track 19-3Others
  • Track 20-1Chickenpox vaccines
  • Track 20-2Tetanus vaccines
  • Track 20-3Rubella vaccines
  • Track 20-4Rotavirus vaccines
  • Track 20-5Pneumococcal vaccines
  • Track 20-6Pertussis vaccines
  • Track 20-7Mumps vaccines
  • Track 20-8Measles vaccines
  • Track 20-9Flu vaccines
  • Track 20-10Hepatitis B vaccines
  • Track 20-11Hepatitis A vaccines
  • Track 20-12Hib Vaccines
  • Track 20-13Polio vaccines
  • Track 20-14Diphtheria vaccines
  • Track 20-15Others
  • Track 21-1Cancer Therapeutic Vaccines
  • Track 21-2Vaccines for Preventive cancer
  • Track 21-3Others
  • Track 22-1Progress and challenges
  • Track 22-2Others